Senior Associate Scientist - Immuno- Oncology Research - South San Francisco, CA | Biospace
Get Our FREE Industry eNewsletter

Senior Associate Scientist - Immuno- Oncology Research

Amgen

Apply
Location:
South San Francisco, CA
Posted Date:
5/23/2017
Position Type:
Full time
Job Code:
R-36391
Salary:
Required Education:
Bachelors Degree
Areas of Expertise Desired:

Job Description

The Department of Oncology at Amgen in South San Francisco is seeking a highly motivated Senior Associate Scientist to perform research studies aimed at elucidating mechanisms of immune-mediated regulation of tumorigenesis in order to develop novel immunomodulatory therapies for the treatment of cancer. The Sr. Associate Scientist will be an integral member of a dynamic research team, collaborating with research scientists at multiple Amgen sites, and working closely with groups in other functional areas including Inflammation, Therapeutic Discovery, and Medical Sciences.

Responsibilities:

Make major scientific laboratory-based contributions to the research goals of the department, present results in both internal and external forums, and participate in the writing of manuscripts for publication.

Planning and performing laboratory experiments, analyzing data, and communicating results.

Requirements

Basic Qualifications:

Master's degree and 3 years of scientific experience

OR

Bachelor's degree and 5 years of scientific experience

Preferred Qualifications:

PhD degree with expertise in one or more of the following areas: multi-color flow cytometry, isolation and culture of primary cells, in vivo models of cancer and/or inflammation, establishing complex cell-based assays, bioinformatics analysis

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.